Influence of comorbidities on clinical outcome in patients (pts) receiving chemotherapy (CT) + bevacizumab (BEV) for primary advanced ovarian cancer (OC). 15. Januar 2018 Woopen, H., Wimberger, P., Mustea, A., Oskay-Oezcelik, G., Keller, M., Richter, R., Harde, J., Klawitter, S., Wegenaer, A., Tomé, O., Sehouli, J., 2017. Ann Oncol 28 (Supplement 5)(956P), 340. doi:10.1093/annonc/mdx372 Abstract Impact of body mass index (BMI) on outcome in 785 patients (pts) receiving systemic chemotherapy (CT) and bevacizumab (BEV) for primary advanced ovarian cancer (OC). Sehouli, J., Mustea, A., Oskay-Özcelik, G., Gabowski, G., Keller, M., Richter, R., Harde, J., Klawitter, S., Wegenaer, A., Tomé, O., Wimberger, P., 2017. Ann Oncol… Weiterlesen Interim Results from PAZOREAL: A Non-interventional Study to Assess Effectiveness and Safety of Pazopanib and Everolimus in the Changine mRCC Treatment Landscape. Bedke, J., Welslau, M., Boegemann, M., Schostak, M., Hering-Schubert, C., Petzoldt, A., Wolf, T., Schleicher, J., Doehn, C., Grüllich, C., Grünwald, V., Steiner, T., Ehness,… Weiterlesen